Our Parkinson's Place: NeuroDerm starts phase III trial of NDO612L in Parkinson's disease

I HAVE PARKINSON'S DISEASES AND THOUGHT IT WOULD BE NICE TO HAVE A PLACE WHERE THE CONTENTS OF UPDATED NEWS IS FOUND IN ONE PLACE. THAT IS WHY I BEGAN THIS BLOG.

I COPY NEWS ARTICLES PERTAINING TO RESEARCH, NEWS AND INFORMATION FOR PARKINSON'S DISEASE, DEMENTIA, THE BRAIN, DEPRESSION AND PARKINSON'S WITH DYSTONIA. I ALSO POST ABOUT FUNDRAISING FOR PARKINSON'S DISEASE AND EVENTS. I TRY TO BE UP-TO-DATE AS POSSIBLE.

I AM NOT RESPONSIBLE FOR IT'S CONTENTS. I AM JUST A COPIER OF INFORMATION SEARCHED ON THE COMPUTER. PLEASE UNDERSTAND THE COPIES ARE JUST THAT, COPIES AND AT TIMES, I AM UNABLE TO ENLARGE THE WORDING OR KEEP IT UNIFORMED AS I WISH. IT IS IMPORTANT TO UNDERSTAND I AM A PERSON WITH PARKINSON'S DISEASE. I HAVE NO MEDICAL EDUCATION,

I JUST WANT TO SHARE WITH YOU WHAT I READ ON THE INTERNET. IT IS UP TO YOU TO DECIDE WHETHER TO READ IT AND TALK IT OVER WITH YOUR DOCTOR. I AM JUST THE COPIER OF DOCUMENTS FROM THE COMPUTER. I DO NOT HAVE PROOF OF FACT OR FICTION OF THE ARTICLE. I ALSO TRY TO PLACE A LINK AT THE BOTTOM OF EACH ARTICLE TO SHOW WHERE I RECEIVED THE INFORMATION SO THAT YOU MAY WANT TO VISIT THEIR SITE.

THIS IS FOR YOU TO READ AND TO ALWAYS KEEP AN OPEN MIND.

PLEASE DISCUSS THIS WITH YOUR DOCTOR, SHOULD YOU HAVE ANY QUESTIONS, OR CONCERNS. NEVER DO ANYTHING WITHOUT TALKING TO YOUR DOCTOR FIRST..

I DO NOT MAKE ANY MONEY FROM THIS WEBSITE. I VOLUNTEER MY TIME TO HELP ALL OF US TO BE INFORMED.

I WILL NOT ACCEPT ANY ADVERTISEMENT OR HEALING POWERS, HEALING FROM HERBS AND ETC. UNLESS IT HAS GONE THROUGH TRIALS AND APPROVED BY FDA. IT WILL GO INTO SPAM.

THIS IS A FREE SITE FOR ALL WITH NO ADVERTISEMENTS

THANK YOU FOR VISITING! TOGETHER WE CAN MAKE A DIFFERENCE!

Monday, August 29, 2016

NeuroDerm starts phase III trial of NDO612L in Parkinson's disease

Aug. 29, 2016

Image: Parkinson’s disease is a progressive neurodegenerative illness characterized by reduced dopamine levels in the brain. Photo: courtesy of dream designs at FreeDigitalPhotos.net.

Clinical stage pharmaceutical firm NeuroDerm has started a phase III clinical trial, evaluating NDO612L for the treatment of Parkinson's disease (PD).

ND0612L is a low-dose continuous subcutaneously administered levodopa/carbidopa liquid formulation. Parkinson’s disease is a progressive neurodegenerative illness characterized by reduced dopamine levels in the brain.

The multicenter, double-blind, placebo-controlled international study, iNDiGO, will randomize 150 subjects to receive either a continuous infusion of ND0612L or placebo replaced every 24 hours for 16 weeks.

The trial is designed to compare ND0612L therapy to oral standard-of-care apart from placebo.

The primary endpoint is the change from baseline to week 16 in the mean percentage of OFF time during waking hours as measured by patients’ home diary assessments.

NeuroDerm reduced the number of patients targeted for enrollment to 150 from 200-240 depending on observed and expected treatment effect.

In the earlier phase II trial, adjunct ND0612L therapy was demonstrated to maintain high trough LD plasma levels and to reduce OFF time by two hours compared to the control arm, oral standard-of-care with placebo.

The iNDiGO trial is expected to complete in 2017. ND0612L is further being developed for future delivery via a small patch pump that is expected to provide a new level of therapy convenience.

NeuroDerm CEO Oded Lieberman said: “The initiation of the iNDiGO trial marks another important milestone in the development of ND0612L as part of our Parkinson’s disease treatment pipeline.

“We believe that ND0612L holds tremendous potential in providing PD patients with a simple, continuous levodopa delivery treatment option that does not require surgery.”

http://clinicaltrials.pharmaceutical-business-review.com/news/neuroderm-starts-phase-iii-trial-of-ndo612l-in-parkinsons-disease-290816-4990653